Amneal Pharmaceuticals, Inc. AMRX AvKARE — Operating Income (Loss)
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — operating income (loss).
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s avkare — operating income (loss)?
- Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — operating income (loss) of $22.4M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s avkare — operating income (loss) changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s avkare — operating income (loss) increased by 73.5% year-over-year, from $12.91M to $22.4M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s avkare — operating income (loss)?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s avkare — operating income (loss) has grown at a 87.3% compound annual growth rate (CAGR), from $6.8M to $83.62M.
- What does avkare — operating income (loss) mean?
- Measures the core profitability of the business segment by subtracting operating expenses from gross profit. It serves as a primary indicator of the segment's operational efficiency and ability to generate earnings from its specific product portfolio.